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To share and gain expertise in toxicogenomics
and to develop a framework for reviewing data,
pharmacology and toxicology reviewers and
researchers within the U.S. Food and Drug
Administration (FDA) Center for Drug
Evaluation and Research (CDER) formed the
Nonclinical Pharmacogenomics Subcommittee
(NPSC) (CDER 2004). The NPSC has
reviewed data from several “mock submissions”
of nonclinical studies that were voluntarily sub-
mitted to the committee or to review divisions.
The term “mock submissions” is used in this
report as opposed to “voluntary submissions’’
discussed in the FDA pharmacogenomics data
submissions guidance (FDA 2005b), which are
to be reviewed by the FDA Interdisciplinary
Pharmacogenomics Review Group (CDER
2005a, 2005b). From this work, the NPSC
gained insight into toxicogenomics data sub-
missions and identiﬁed areas that might need
additional consideration before full integration
of this technology into routine drug develop-
ment. In this article we summarize the most
useful portions and identify potentially un-
necessary details in these mock submissions and
provide insight as to how CDER reviewers
assess submissions of pharmacogenomics data.
General Description 
of Mock Submissions
The NPSC examined in detail three mock
submissions that addressed different uses of
pharmacogenomics data during drug develop-
ment. The topics addressed by the mock sub-
missions were a) microarray data quality using
a data set generated for a single compound,
b) assessment in a single tissue of the effects of
several compounds in a pharmacological class,
and c) use of a proprietary database to help
classify a compound of unknown toxicity.
None of the submissions involves a com-
pound that is the subject of an active investi-
gational new drug (IND) or new drug
application (NDA). Further, these studies
were not conducted under Good Laboratory
Practice (GLP) regulations for nonclinical
studies regulations (FDA 2002), and devia-
tions from GLP were not described in the
submissions. The NPSC did not judge the sci-
entiﬁc merit of the conclusions reached by the
sponsor of each mock submission but rather
considered the experimental design, organiza-
tion of data, and adequacy of the information
available to support the hypothesis, including
the relationship of the genomics data to the
general toxicology data.
The NPSC evaluated the content of the
mock submissions using the framework for
reporting microarray data outlined by the
Microarray Gene Expression Data (MGED)
Society in their proposals of the minimum
information about a microarray experiment
(MIAME) (Brazma et al. 2001; MGED
Society 2002). The ﬁelds speciﬁed in MIAME
present a foundation for content necessary for
review of pharmacogenomics data. More
recently, a framework for reporting biological
investigations across “omics” technologies has
been initiated through the MGED Society
that includes an investigational design descrip-
tion checklist, a discipline-specific checklist
[e.g., MINTox (minimum information
needed for a toxicology experiment)], and a
technology-based checklist (e.g., MIAME)
(MGED Society 2004). The mock submis-
sions were not speciﬁcally prepared according
to the MIAME/MINTox recommendations;
however, one submission was prepared to con-
form to the speciﬁcations of the draft pharma-
cogenomics guidance (FDA 2003).
We describe in detail the three submis-
sions in the sections that follow, with the
sponsor’s conclusions and the NPSC com-
ments for each submission. Table 1 summa-
rizes the formats for various parameters used
in each submission.
Submission 1: Assessment 
of Data Quality for Microarray
Studies on a Single Agent
Submission description. The mechanism of
action of a compound purported to reduce
cholesterol levels by inhibiting HMG-CoA
(3-hydroxy-3-methylglutaryl coenzyme A)
reductase was investigated in female rats. The
compound was administered daily by oral
gavage at three dose levels for 1 month.
Observations and measurements included clini-
cal assessments (including body weights and
food consumption), serum chemistry, macro-
scopic and microscopic evaluations of kidney
and liver, and quantitative polymerase chain
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Researchreaction (qPCR) of HMG-CoA reductase and
cytochrome P450 (CYP)1B1 and CYP2B2 gene
expression in rat liver. The report included all
the data except for the histopathological ﬁnd-
ings in kidney and liver. Detailed protocols for
microarray assay steps from RNA isolation to
array scanning were provided in the submis-
sion. Gene expression analysis of liver samples
collected 1, 7, or 30 days after drug administra-
tion was performed using Affymetrix (Santa
Clara, CA) Rat Genome U34 Microarrays.
Only the concurrent control and high-dose
groups were analyzed for gene expression
changes.
The submission addressed the potential use
of controls to monitor different steps in
microarray experiments. Although labeling
controls to monitor the efficiency of target
preparation were not included in the mock
data set, the sponsor included proprietary data
on the use of polyadenylated transcripts of
three Bacillus subtilis genes (lys, phe, and thr;
GenBank accession nos. X17013, M24537,
X04603, respectively; http://www.ncbi.nih.
gov/GenBank) to illustrate how this informa-
tion might be incorporated in an actual
microarray data submission. Hybridization
controls to determine the sensitivity and qual-
ity of hybridizations included the measurement
of BioB, BioC, and BioD genes (GeneBank
accession no. J04423; http://www.ncbi.nih.
gov/GenBank/) of the Escherichia coli biotin
synthesis pathway and the cre recombinase
gene for P1 bacteriophage (GeneBank acces-
sion no. X03453; http://www.ncbi.nih.gov/
GenBank/). Data from these hybridization
controls were provided in tabular and graphic
form, including an analysis of the dynamic
range. The sponsor also discussed the possible
use of batch controls to monitor technical
variability and equipment controls to ensure
microarray image quality.
The submission included a comprehensive
section on quality control (QC) metrics. The
sponsor provided examples based on their gen-
eral laboratory experience to demonstrate the
possible use of QC metrics for RNA and cRNA
because these metrics were unavailable for the
submitted data set. RNA quality was assessed
by 28S:18S ratios and percent area (deﬁned as
the percentage of the total RNA population
that is derived from the 18S and 28S rRNA
bands). For cRNA, in vitro transcription yield
and the ratio of absorbance at 260 and 280 nm
were proposed as QC metrics. QC metrics gen-
erated by Affymetrix Microarray Suite 5.0
(MAS5: Affymetrix) software from scanned
images (i.e., background, noise, scaling factor,
percent absent, 3´:5´ ratios) were used to assess
the quality of the hybridizations.
These metrics informed a paradigm for
rejection of array data. Further, hybridization
images were inspected for signal level, presence
of image defects, and appropriate grid align-
ment at the edges and corners. Reproducibility
between biological replicate hybridizations
(correlation, detection call agreement, and
< 2-fold signal value difference) was presented
as a scatter plot and in tabular form. The bias
in the data due to scanning of control and
treated samples on different days was identi-
ﬁed through examination of the data for the
hybridization controls. The bias was mitigated
by using a permutation analysis to reduce the
number of false positives and by considering
the biological relevance of the differentially
expressed genes.
Sponsor’s conclusions. Analysis of changes
in liver gene expression was conducted to
further understand the pharmacological
mechanism of action of the compound
through examination of its primary genomics
target in the cholesterol biosynthesis pathway.
The compound showed no significant treat-
ment-related toxicity in the liver at the tested
doses. A heat map was generated to compare
samples collected from treated and control
animals at different time points after drug
administration. The heat map illustrated pos-
sible co-regulated genes that clustered by
direction and extent of regulation at each time
point. Changes in expression levels of genes
encoding enzymes from relevant biochemical
pathways were shown in ﬁgures and discussed
in the text. The data were consistent with cur-
rent understanding of cholesterol biosynthesis.
NPSC comments. The content and organi-
zation of the mock submission were a collabo-
rative exercise between the NPSC and the
sponsor. A preliminary technical plan was pre-
sented to the NPSC and followed by a draft
proposal before the final mock submission.
The sponsor submitted very extensive informa-
tion on laboratory and informatics infrastruc-
ture. Such extensive information may not need
to be included in all genomics data submis-
sions where a summary is generally sufﬁcient.
However, this information should be well doc-
umented and available on request, possibly as
part of a device master ﬁle or standard operat-
ing procedures (SOPs). Although the text of
the submission contained information allowing
a reviewer to trace a sample from the animal
source to its corresponding array data set, it
would have been helpful for the sponsor to
provide a key in electronic ﬁle format to link
these ﬁles.
The sponsor submitted a comprehensive
section on QC measurements. The NPSC
concluded that these parameters appeared
Leighton et al.
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Table 1. Format of content in the mock submissions.
Parameter Submission 1 Submission 2 Submission 3
Study design Supplied in both MS Word and PDF formats In PDF ﬁle In MS Word document
Toxicology In SAS transport ﬁles Complete reports, including TEM, in PDF ﬁles In MS Word document; molecular
pharmacology results also provided
Microarray platform Affymetrix GeneChip (rat genome U34  Affymetrix GeneChip (human HGU95Av2 CodeLink RU1 Expression BioArrays (rat)
arrays) arrays)
Microarray protocol information Affymetrix EXP ﬁles Not provided In MS Word document
QC metrics Affymetrix RPT ﬁles and RNA QC metrics Results from Affymetrix RPT ﬁles combined Agilent Bioanalyzer electropherograms, QC
(see text) in a single TXT ﬁle metrics for RNA and arrays, and correlation
to historic control data provided in
MS PowerPoint and MS Excel ﬁles
Raw expression data Array images as low-resolution ﬁgures in Not provided Array images provided as TIFFs
Word document
Processed expression data Provided in XML, CHP, CEL, and SAS MAS5 signals and detection calls Provided in TXT ﬁles
transport ﬁles
Interpreted expression data Subsets of signiﬁcantly changes genes in PCA results provided as bitmaps and Two-dimensional hierarchical clustering,
MS Excel ﬁles; affected pathways in interpreted in PDF ﬁle Pearson’s correlation, linear discriminant
MS PowerPoint ﬁles signature analysis, pathway analysis
Statistical analysis Affymetrix MAS5 using two different data Rosetta Resolver (version 3.2) (p-values, Tools in proprietary database
normalization algorithms fold-change, and other parameters)
Notable inclusions A detailed description of the statistical A separate tab-delimited text ﬁle contained Contextual gene expression and drug
preprocessing of expression data, ﬁltering, data for all probe sets with a p-value < 0.05 signature analysis; electronic ﬁle
normalization, and modeling methods tracking key
Abbreviations: EXP, experiment information ﬁle; MS, Microsoft; PDF, portable document format; RPT, report ﬁle; TEM, transmission electron microscopy; TIFF, tagged image ﬁle format;
TXT, text ﬁle.adequate. The electronic ﬁles were organized
to be consistent with FDA guidance (FDA
1999). The NPSC noted the importance of
electronic data sets, even for subsets of genes.
The utility and suitability of particular elec-
tronic formats will depend on whether these
ﬁles are used to populate a database with data-
mining capabilities or as a data repository. In
the review of electronic microarray data, the
NPSC noted the need for user-friendly soft-
ware tools to analyze and visualize data. It was
apparent that reviewers will need appropriate
training and software to effectively manipulate
microarray-associated data.
The NPSC observed that, in general, the
protocols for the in-life portion of toxico-
genomics studies should follow practices used
for standard toxicity studies. These include the
use of both sexes (unless there is scientiﬁc jus-
tification to limit the study to one sex) and
using appropriate doses of drug. The number
of replicates and power needed will vary
depending upon the sponsor’s intended claim
and the experimental objectives (Simon et al.
2002). However, in order to perform some
minimal statistical analysis, at least three ani-
mals per sex per time point are generally
needed. Often, it may be necessary to use doses
of drug large enough to induce the toxicity or
pharmacologic activity that is related to the
genomics target being studied. Gene expression
changes that are critical to the sponsor’s argu-
ment may be conﬁrmed with qPCR on a lim-
ited number of genes. The NPSC believed that
this strengthened the experimental data in this
submission, considering the limited experience
with gene expression data and the continuing
evolution of the technology. Differences
between sample collection methods (transverse
vs. longitudinal sectioning) for histopathology
and genomics analysis were not explained and
could be considered a complicating factor in an
analysis. The NPSC also agreed that it would
facilitate review if the animal data portions of
toxicogenomics studies were submitted in the
format of a standard GLP toxicology study.
In general, the NPSC agreed that sufﬁcient
data were available to support the mechanism
of compound action proposed by the sponsor.
The NPSC considered the use of clustering
analysis to identify co-regulated genes to be
primarily hypothesis generating. Pharmaco-
genomics data that explore the presumptive
mechanism of action of a compound may
enhance traditional toxicology studies.
Submission 2: Assessment in a
Single Tissue of the Effects of
Several Compounds in a Class
Description. The potential human liver toxic-
ity of compounds used to treat dyslipidemia
was evaluated by treating male cynomolgus
monkeys with one of three drugs. The test
articles included two marketed peroxisome
proliferator α-agonists (PPARα; fenofibrate
and ciproﬁbrate) and a proprietary PPAR pan-
agonist compound (PPARpan) with activity
on PPARα, γ, and δ receptors. A vehicle con-
trol was also included. In the deﬁnitive study,
monkeys (four per group) were treated for
15 days with a single dose of PPARpan or sev-
eral dose levels for fenoﬁbrate or ciproﬁbrate,
respectively. Doses for fenoﬁbrate and ciproﬁ-
brate in the 15-day study were based on a
4-day dose-range–ﬁnding study. In vivo study
observations included clinical evaluations
(including body weight and food consump-
tion), clinical chemistry and hematology, and
toxicokinetics. At necropsy, organ weights
were determined and macroscopic evaluation
conducted. The sponsor used SOPs in con-
ducting the toxicology portion of the study.
The livers were examined using both light
microscopy and transmission electron
microscopy (TEM). Enzymatic activity of
components of β-oxidation pathways was also
assessed in these samples.
Liver sections were collected for toxico-
genomics analysis from all animals. RNA was
isolated and the expression proﬁle was exam-
ined using the manufacturer’s standard proto-
cols with Affymetrix GeneChip HGU95Av2
arrays. The mock submission provided limited
information about the protocols because these
protocols are publicly available. Samples
reported included control and high-dose ani-
mals from the range-ﬁnding study and all ani-
mals in the deﬁnitive study.
Sponsor’s conclusions. To further under-
stand the toxicity associated with PPARpan,
the sponsor analyzed microarray data using
principal component analysis (PCA) to exam-
ine the relationship between control and
treatment groups in both the 4-day dose-
range–ﬁnding study and the 15-day deﬁnitive
study. The samples from animals treated for 4
and 15 days clustered differently. The sponsor
attributed these differences to technical fac-
tors based on a similar separation among 4-
and 15-day control animals. One 15-day con-
trol animal clustered away from other samples
in the same treatment group and thus
appeared to be an outlier. Ciproﬁbrate-treated
samples clustered more tightly by dose level
than fenoﬁbrate-treated samples and demon-
strated more pronounced dose–response alter-
ations in gene expression. The single-dose
level of PPARpan induced a modest alteration
in gene expression. Using PCA, PPARpan
effects appeared similar to those of the higher
dose levels of fenoﬁbrate.
The sponsor assumed that the human-
based probe sets with a MAS5 detection call of
“present” were hybridizing to the correct
homologous monkey sequence and that the
data were interpretable because the objective
was to compare gene expression between
control and treated groups. Previous studies
have demonstrated that cRNA from macaque
and rhesus monkeys effectively hybridizes with
a human Affymetrix GeneChip (Chismar
et al. 2002; Enard et al. 2002), although a
recent study (Gilad et al. 2005) found a large
effect of sequence divergence on hybridization
signal. The sponsor concluded that some of
the interanimal variability seen in this study
may be due to greater genetic heterogeneity of
monkeys compared with laboratory rodents
and to imperfect hybridization of monkey
cRNA to the human array.
Treatment-related effects were noted in
clinical observations and serum chemistry,
particularly at the highest doses. Liver changes
reported at some or all drug-treatment groups
included hypertrophy, increased liver weights,
eosinophilia and granularity of the cytoplasm,
and single-cell necrosis consistent with apop-
totic cell death. This last finding was not
observed with PPARpan. TEM evaluation
indicated that all compounds increased peroxi-
some and mitochondria number as well as
mitochondrial area. Activity of some enzymes
of β-oxidation was increased in livers of
ciproﬁbrate- and fenoﬁbrate-treated animals.
Further interpretation of the gene expression
results, for example, regarding induction of
apoptosis, has subsequently been performed
by the sponsor (Cariello et al. 2005).
NPSC comments. The initial submission
consisted of separate toxicology and gene
expression study reports of the same experi-
ments. Although some experimental data such
as animal treatment and husbandry were avail-
able through cross-reference to other protocols,
this submission would have been easier to
review if it had been organized as an integrated
report using a format like MIAME/MINTox.
Data for QC metrics were provided in the
submission, but graphical presentation of
some metrics would have aided the review.
The toxicology data were very helpful in
interpreting the difference in gene expression
results between the PPARα compounds and
PPARpan. The electron microscopy and mor-
phometry analysis of peroxisomes and mito-
chondria provided additional detail relevant
to the toxicogenomics assessment.
Inclusion of electronic files in the mock
submission made it possible to independently
analyze the sponsor’s results. The NPSC used
Spotfire software (Spotfire Inc., Somerville,
MA) to analyze the microarray data from the
4- and 15-day experiments. The NPSC chose
not to analyze these data sets together because
the significant technical variation between
them might confound the analysis of biological
relatedness between PPARpan and PPARα
agonists. Cariello et al. (2005) noted that poor-
quality RNA was obtained from one control
animal and that the arrays from the 4-day
non-GLP study and the 15-day GLP study
were processed on different days by different
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trols and treated groups for each day were
processed together. Therefore, the results for
the treated groups can be compared separately
with the results for the appropriate control.
PCA by the NPSC of individual samples
from the 15-day experiment showed that most
samples did not form tight clusters within their
treatment groups (Figure 1). This indicated
that gene changes at the low dose were as likely
to be related to biological and technical varia-
tion as to drug treatment. In contrast, a clear
dose-related separation was observed for the
ciprofibrate treatment. In this analysis,
PPARpan samples clustered in the same region
of the PCA as the control and low-dose treat-
ment samples. This differed from the sponsor’s
conclusions, which were derived from an
analysis using both 4- and 15-day treatment
groups. Additionally, the NPSC concluded
that the control animal in the 15-day experi-
ment identiﬁed as an outlier by the sponsor did
not appear to be more distant from other con-
trol samples in the PCA when compared with
other dose group distance variations. Although
PCA is a valuable method to inspect sample
homogeneity and general treatment-related
changes in gene expression data, it is a subjec-
tive and relative method of analysis. Additional
analyses of the data (e.g., using heat maps,
pathway analysis) would have been useful to
provide more support for the conclusions.
These analyses have subsequently been per-
formed and published by the sponsors
(Cariello et al. 2005).
Although cross-species hybridization is not
an ideal approach, there are limitations in the
available arrays for speciﬁc animal models. The
sponsor acknowledged this fact and attempted
to address it by providing confirmatory evi-
dence with additional studies. With the advent
of arrays for additional laboratory species,
including the monkey, this technical challenge
is not expected to be a major regulatory
concern in the future.
Despite the technical problems encoun-
tered and the different conclusions reached by
the sponsor and the NPSC, this submission
provided an example of the incorporation of
gene expression analysis into an overall assess-
ment of the potential toxicity of a new drug
entity compared with a known drug class.
Such an integrated submission potentially
could be used to support a possible mecha-
nism of action or to distinguish compounds
within a pharmacologic class.
Submission 3: Assessment of
Toxicity of a Test Compound
by Comparison with a
Reference Database
Description. The potential toxicity of a selec-
tive serotonin reuptake inhibitor (SSRI) was
assessed in male rats treated daily for 5 days
with vehicle and two dose levels of a test com-
pound. One dose was a nontoxic pharmaco-
logic dose, whereas the high dose was
equivalent to maximum tolerated dose based
on decreases in body weight gain. The results
of molecular pharmacology assays, clinical
observations (including body weights and
food consumption), clinical chemistry and
hematology, selected organ weights, necropsy
observations, and liver histopathology were
provided for four time points (6 hr to 6 days
after the first dose was administered). Liver
samples from individual animals were
obtained and processed separately for micro-
array analysis. Gene expression studies were
conducted using CodeLink RU1 Expression
BioArrays (Amersham Biosciences, Piscataway,
NJ). Expression data for three to six animals
per time point per treatment group dosed for
1, 3, and 5 days were analyzed and compared
with a contextual reference database of
microarray data for approximately 600 com-
pounds. The sponsor provided access to its
proprietary database to allow NPSC members
to independently conﬁrm the gene expression
ﬁndings.
Sponsor’s conclusions. The toxicogenomics
analysis indicated that the SSRI was relatively
nonhepatotoxic, as confirmed by the histo-
pathology findings. The sponsor defined a
drug signature as “a small set of genes that
delineates a property of one class of com-
pounds from another or from vehicle con-
trols.” The use of drug signature analysis
conﬁrmed several effects of the SSRI class that
were observed using traditional pharmacology
and toxicology assays (ion channel blocking
and serum creatinine increase). Signature
analysis suggested potential safety risks of per-
turbed blood pressure regulation and phos-
pholipidosis, but ancillary data were not
available to conﬁrm these ﬁndings.
NPSC comments. This mock submission
demonstrated the use of a contextual database
containing genomics data annotated with tox-
icity data for the interpretation of the poten-
tial toxicity of an SSRI. The comparison of
the pharmacology data and gene signature
proﬁle for this SSRI with similar compounds
in the database also provided an example of
gene proﬁle speciﬁcity. In this example, inde-
pendent veriﬁcation of matches to some gene
signatures was provided by clinical chemistry
and molecular pharmacology assay results.
Matches to other gene signatures could only
suggest potential toxicities, as these are not
probable valid biomarkers. The signatures
would require additional experiments for con-
firmation. Potential toxicities suggested by
gene signatures would be addressed in differ-
ent sections of full IND/NDA submissions
(e.g., safety pharmacology and histopathology
in a longer toxicology study). The submission
contained adequate information on sample
and array quality assessment and on the statis-
tical analyses that were applied to the data.
The NPSC agreed that sufficient data were
available to support the hypothesis proposed
by the sponsor.
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Figure 1. PCA of gene expression signals (expressed as arbitrary units) in cynomolgus monkey liver sam-
ples after 15-day treatment with hyperlipidemia drugs. Cipro, ciproﬁbrate; Feno, fenoﬁbrate.
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and be trained on the database provided an in-
depth understanding of the use of a contextual
database to generate gene expression signatures.
Voluntary submissions may be a suitable route
for sponsors to introduce FDA reviewers to
similar approaches that use large data sets to
generate gene signatures. The NPSC antici-
pates increased use of contextual databases as a
resource for the generation of gene expression
signatures or motifs that could eventually
become validated biomarkers of toxicity.
However, the gene components of these signa-
tures would need to be available for review by
regulators if not generally accepted, that is, a
known valid biomarker, as deﬁned by the FDA
pharmacogenomics guidance (FDA 2005b).
Other Submissions Containing
Pharmacogenomics Data
The NPSC is aware of several nonclinical
pharmacogenomics submissions provided as
part of IND and NDA submissions. These
gene expression studies were designed to
explore the pharmacology of the pharmaceuti-
cal or as an additional tool to investigate an
observed toxicity. As described by the FDA
pharmacogenomics guidance (FDA 2005b),
most of these submissions likely would have
qualiﬁed as voluntary submissions to the IND
or as synopses to the NDA because they were
exploratory studies in which no regulatory
decisions were or could have been made. The
sponsors were not using the pharmaco-
genomics data to make claims regarding safety
or efficacy. The submissions did not involve
either known or probable valid biomarkers.
MIAME/MINTox criteria were not used in
these submissions. All submissions were pro-
vided as paper reports, making it difficult to
assess drug-related effects on gene expression.
Most of these submissions reported only a sub-
set of affected genes, which may be acceptable,
although all data should be available upon
request. In the opinion of the NPSC, submis-
sion of the data in an electronic format would
have facilitated review of these analyses. Some
of these studies were inadequately designed.
Issues included insufﬁcient numbers of animals
per group per time point, too few time points,
use of pooled tissue samples, and lack of QC
metrics (e.g., demonstration of RNA purity).
Adequate documentation and evaluation of
these parameters will be important for future
regulatory submissions.
Conclusions
The application of pharmacogenomics and
toxicogenomics in drug development has 
primarily been used in compound selection
and for identiﬁcation of possible biomarkers of
safety or efﬁcacy. The NPSC anticipates that as
conﬁdence grows in the technology and guide-
lines for its use in a regulatory context are
further delineated, sponsors will increasingly
use it to address issues of regulatory impor-
tance. These may include studies of a drug’s
mechanism of action or further investigation of
a speciﬁc toxicity observed in a clinical or non-
clinical study. The mock submissions described
here serve as a basis for dialog within and out-
side the FDA to address how data are to be
submitted, what data should be submitted, and
what regulatory decisions are likely to be made
with the data submitted.
A structure such as that described by
MIAME/MINTox (MGED Society 2004)
would be useful for review of genomics data
within the context of a drug approval submis-
sion. MIAME/MINTox is a checklist of
information important for independent
review of genomics data within a biological
context. Genomics data submissions were eas-
ier to review when integrated into a standard
toxicology report format. It would be useful
to include pathway analysis and other gene
annotations with lists of gene changes.
Confirmation of gene changes by secondary
analysis (e.g., PCR) may be included to sup-
port conclusions drawn from the genomics
expression analysis. The need for such conﬁr-
mation may depend on the sponsor’s claim
and its impact on the safe use of the drug
being tested. If genomics data were part of a
standard IND/NDA submission, any addi-
tional toxicity suggested by these data would
be addressed in the standard safety pharmacol-
ogy studies and in longer toxicology studies
typically performed during drug development.
Analyses such as PCA were helpful for
identifying general similarities or differences
among samples within or across treatment
groups. Information not normally included in
most submissions of toxicology data and not
speciﬁed in MIAME/MINTox, such as infor-
mation on laboratory informatics and equip-
ment settings, may not be needed for review
but should be available upon request. For
example, information on array design descrip-
tion for commercially available arrays may not
be necessary, but speciﬁcations should be pro-
vided for custom arrays. Quality metrics that
were used for technical evaluation of the
microarrays in these submissions were gener-
ally acceptable, but additional standards may
be necessary for use of gene expression analysis
in nonclinical toxicology assessments during
drug development. It is not clear how much
information regarding technical variation
and equipment efﬁciency will be needed in a
regulatory submission.
The mock submissions were a useful tool
for the NPSC to gain experience in how to
best review toxicogenomics data. Additional
voluntary genomics data submissions as
described in the pharmacogenomics guidance
(FDA 2005b) are encouraged so that the best
practices for handling these data can continue
to be developed. Many issues remain to be
addressed. These include but are not limited
to the amount of data needed to support a
study’s conclusion, methods for the statistical
evaluation of microarray data, the complexity
of pathway analysis, and the need to make
decisions concurrently with advances in
related disciplines such as cell biology and
molecular medicine.
The FDA has co-hosted several workshops
on pharmacogenomics and drug development
with groups representing pharmaceutical
manufacturers and the biological industry.
Additional workshops are planned in the near
future. Consortia have been formed to con-
tinue dialogue between regulators, industry
groups, and academicians on these topics
under the umbrella of organizations such as
the International Life Sciences Institute (ILSI)
through the ILSI–Health and Environmental
Sciences Institute initiative (Pennie et al.
2004). The Clinical Data Interchange
Standards Consortium nonclinical working
group is developing hypothetical case exam-
ples to address speciﬁc toxicity issues, with the
goal of enhancing the development and accep-
tance of toxicogenomics data standards (Lord
and Papoian 2004). In time, this ongoing dia-
logue and additional opportunities to review
genomics data promise to lead to a more rapid
development program for novel pharmaceuti-
cals, as envisioned by the FDA’s Critical Path
Initiative (FDA 2004).
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